LAS VEGAS, Sept. 16, 2026 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce the completion of its USD $5.5 million acquisition of the La Vencedora mining concession, a high-grade underground gold and silver property located in the Etzatlán region of Jalisco, Mexico.

The La Vencedora concession covers approximately 1,200 hectares, and the completed acquisition has provided AABB with 100% ownership of the mining concession. In conjunction with the closing, the Company completed its legal and technical due diligence on the mining concession, as well as all associated ownership and title documentation.

In accordance with the terms of the acquisition, 50% of the $5.5 million purchase price will be paid in cash immediately, with the remainder payable in installments. No AABB common shares will be issued as part of the acquisition. The structure of the deal enables AABB to acquire the property without any shareholder dilution and with financial flexibility to develop and produce the property.

Following the Company’s previously announced Letter of Intent, the completion of the acquisition will enable the Company to progress towards mine preparation and extraction with initial mineralized material targeted for processing at the AABB Etzatlán gold and silver processing facility in Q4 2026. The La Vencedora mine is located approximately 18 kilometers from the AABB Etzatlán processing facility, thus enabling the extracted mineralized material to be transported directly to the Company’s existing processing facility.

Historically, the Company has obtained information about gold grades ranging from approximately 9 grams per ton (g/t) to 12 g/t and silver grades ranging from approximately 350 g/t to 400 g/t. These historical grades have been incorporated into the current mine plan and technical evaluations and do not constitute an estimate of the current mineral resource or reserves. La Vencedora is not an undeveloped exploration property. The mine contains approximately 1.3 kilometers of underground development on multiple levels and access points, and thus provides existing infrastructure to enable the Company to proceed with its initial mining program.

The existing underground development of the property is expected to help in reducing the initial development costs, compared with a new greenfield underground operation. Consequently, the Company will be able to focus its efforts on mine rehabilitation and production. Based on the current internal mine plan and technical evaluation, AABB expects to produce approximately 150 to 200 tons per day of mineralized underground material from the La Vencedora mine into the Etzatlán processing facility. This estimate is subject to mine development, grade continuity, equipment availability, extraction and processing performance.

The La Vencedora material will help the Company increase the Etzatlán production feed with another source of higher-grade material. Actual feed rate to the processing facility will be based on the production schedule, feed characteristics and processing performance. The underground hard-rock material is also expected to provide a relatively consistent flotation feed material to complement the Company’s existing surface and stockpile feed material. Management believes that this should improve the flexibility of the Etzatlán facility in blending the feed material and decrease certain difficulties in processing it.

Etzatlán processing facility utilizes extensive flotation system for processing mineralized rocks, and the characteristics of the underground material from La Vencedora are well-matched with the processing facilities. With the acquisition completed, AABB’s mining and technical teams will be working on mine preparation, rehabilitation, sequencing of initial extraction zones, equipment and personnel deployment, logistics and transportation planning and preparation of the material transportation and processing at the Etzatlán facility.

The Company targets the start of the extraction activities during Q4 2026, followed by delivering and processing of initial La Vencedora material at the Etzatlán processing facility. “The completion of the La Vencedora acquisition significantly improves our Etzatlán mining district,” said Chris Torres, AABB President and CEO. “We now own 1,200 hectares containing 1.3 kilometers of underground development at only 18 kilometers from our processing facility. Based on our current internal mine plan, we expect La Vencedora to provide approximately 150 to 200 tons per day of underground material to the Etzatlán processing plant.”

Torres added, “The structure of the deal is also beneficial for our shareholders, as 50% of the purchase price will be paid in cash immediately, the remainder payable in installments, and no AABB common shares will be issued. Our immediate focus is now on mine preparation and rehabilitation and the start of the La Vencedora production in Q4.”

The Company expects to provide additional updates as the development proceeds, including the initiation of the extraction program, production schedule, deliveries of mineralized material, processing volumes and the commencement of production from the La Vencedora material at the Etzatlán processing facility. AABB continues seeking opportunities to increase its precious metals production and properties portfolio in Mexico, particularly those most suitable to leverage the Company’s established processing facilities in Etzatlán.

About Asia Broadband

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production of precious metals and the accumulation of physical gold and silver holdings. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate the expansion of precious metals property holdings and production in Mexico. The Company’s industry and business integration in Mexico and its asset diversification are unique strengths of AABB that differentiate it from other companies and creates distinctive value for shareholders. Additionally, the Company has a digital assets business segment with its AABBG and AABBS mine-to-token gold and silver-backed cryptocurrencies within its own proprietary GoldAxis Wallet and the unique Golden Baboons Mining Club and Shorts Rascal Club Non-Fungible Token (NFT) collections. AABB expects its token to become a world-wide standard of exchange that is stable, secured and trusted with gold backing, while having the added benefit of demand based price appreciation. These are unique and outstanding qualities relative to other cryptocurrencies and digital asset developers.

Contact the Company at:

General Email: ir@asiabroadbandinc.com
Token Support: support@aabbgmine2token.com
Company Websites: www.asiabroadbandinc.com
  www.aabbgmine2token.com
  www.goldenbaboons.com
 
Phone: 702-744-4785
 

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Asia Broadband Inc.’s (the “Company”) expected current beliefs about the Company’s business, which are subject to uncertainty and change. The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory, market and competitive circumstances change. Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website. The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

Source: Asia Broadband Inc.

Exclusive collaboration debuts RMCF’s first-ever Miso Caramel, with only 250 available per participating store

DURANGO, Colo., Sept. 16, 2026 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company” or “RMCF”), America’s Chocolatier® since 1981, today announced an exclusive limited-edition collaboration with Miraculous Corp’s Miraculous: Tales of Ladybug & Cat Noir, bringing the globally recognized entertainment franchise to select Rocky Mountain Chocolate Factory locations with a new limited-edition caramel apple.

Available September 15 through October 31, 2026, while supplies last, the Miraculous® Miso Caramel Apple features a Miso Caramel formulation developed exclusively for Miraculous®, marking the first time Rocky Mountain Chocolate Factory has offered the flavor in its stores. Only 250 Miraculous® Miso Caramel Apples will be available at each participating Rocky Mountain Chocolate Factory location, presented in exclusive limited-edition Miraculous® packaging.

Rocky Mountain Chocolate Factory and Miraculous Corp Unveil Limited-Edition Miso Caramel Apple

A New Take on an RMCF Icon
The Miraculous® Miso Caramel Apple features a crisp apple dipped in Rocky Mountain Chocolate Factory’s new Miso Caramel. One half is finished with crunchy salted pretzel pieces, while the other is left smooth to showcase the Miso Caramel itself. The half-and-half design takes inspiration from Marinette’s transformation into Miraculous Ladybug, representing the progression from the everyday to the extraordinary. The combination brings together sweet, salty, and savory flavors in a distinctive interpretation of one of Rocky Mountain Chocolate Factory’s most recognizable products. The launch also taps into a growing sweet-and-savory flavor trend. Yelp’s January 2026 Trend Tracker reported that searches for “miso caramel” increased 107% year-over-year.

“We see collaborations like Miraculous® as an exciting way to introduce Rocky Mountain Chocolate Factory to new audiences while creating something unexpected for guests who already know and love us,” said David Denker, Chief Operating Officer of Rocky Mountain Chocolate Factory. “We wanted this Miraculous® collaboration to feel truly special, not simply like another seasonal product. Our team created a completely new flavor, bringing together sweet, salty and savory flavors in a way our guests have never experienced at RMCF. Even the design of the apple tells part of the story. From the flavor and texture to the limited-edition packaging and in-store experience, we wanted every element to feel intentional, fun to discover, and connected to the world of Miraculous®.”

Ashley Depp, Miraculous Corp.’s Senior Vice President of Marketing & Franchise, added, “Miraculous® has always celebrated the idea that heroes can be found in everyday life, and that even an ordinary moment can become something extraordinary. This collaboration with Rocky Mountain Chocolate Factory brings that spirit to life, giving families and fans a chance to share a treat, discover something new, and create their own Miraculous moment together.”

Innovation Meets Experiential Retail
For Rocky Mountain Chocolate Factory, the collaboration reflects a broader focus on developing new partnerships that create excitement and in-store experiences that invite new audiences and give existing fans another reason to visit. The Miraculous® activation combines product innovation and storytelling with the sights, smells, tastes and live candy-making theater that have defined Rocky Mountain Chocolate Factory for more than four decades. The franchise is also a global digital powerhouse, with 53 million subscribers and 55 billion lifetime views across more than 50 official YouTube channels. On TikTok, the brand boasts more than 1 billion views and 7 million followers.

Guests can follow Rocky Mountain Chocolate Factory and Miraculous social channels for product reveals, participating locations, in-store content and additional updates throughout the collaboration.

About Rocky Mountain Chocolate Factory, Inc.
Rocky Mountain Chocolate Factory, Inc. is a leading franchisor, manufacturer and retailer of premium chocolates and other confectionery products. As America’s Chocolatier® since 1981, the Company produces an extensive assortment of premium chocolates, gourmet caramel apples and other handcrafted confections. Headquartered in Durango, Colorado, Rocky Mountain Chocolate Factory is ranked among Entrepreneur’s Franchise 500® for 2026. Together with its franchisees and licensees, the Company operates approximately 250 Rocky Mountain Chocolate Factory locations across the United States and internationally. The Company’s common stock is listed on the Nasdaq Global Market under the symbol “RMCF.”

About Miraculous Corp
Miraculous Corp is the groundbreaking joint venture between Mediawan and ZAG established in 2024 to unite all facets of the globally acclaimed Miraculous® franchise. Headquartered in the United States, and with a creative studio based in Paris, Miraculous Corp oversees the franchise’s creative vision and commercial strategy to expand the Miraculous universe and its global footprint, ushering in a new era of iconic characters and captivating narratives.

Driven by a mission to inspire future heroes to change the world, Miraculous Corp creates stories that empower and engage kids and family audiences everywhere. The company’s dynamic portfolio includes the flagship property Miraculous: Tales of Ladybug & Cat Noir. Season seven is in production for a late 2026 launch, and a theatrical feature is in development, produced by John Cohen (Despicable Me). The portfolio also includes the Miraculous® Chibi (52 x 3′), as well as Miraculous® Stellar Force (26 x 22′), the first original spin-off series in the Miraculous® universe.

Mediawan is Europe’s premier independent production powerhouse led by Pierre-Antoine Capton, known for acclaimed titles such as Miraculous, Adolescence, Call My Agent, 3 Body Problem, HIP, The Count of Monte Cristo, and Rhythm and Flow. ZAG, the innovative independent animation studio led by Jeremy Zag, has gained global recognition for creating the ZAG HEROEZ label, including Miraculous and Ghostforce.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future operational initiatives, strategic priorities, product innovation, franchise growth, and shareholder value creation. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Investor Contact
Sean Mansouri, CFA
Elevate IR
(720) 330-2829
RMCF@elevate-ir.com

Media Contact
Raymond Barrett
Director of Marketing
(305) 801-5641
rbarrett@rmcf.net

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b1c4c2b-7f85-40a9-93cc-a13b6c6a7186

New York, New York, Sept. 16, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) (“Antelope Enterprise”, “AEHL” or the “Company”), which provides livestreaming ecommerce services, business management and information systems consulting services in China, today announced the closing of its previously announced offering of 8.00% convertible promissory notes in an aggregate principal amount of $6.0 million (the “Note”) to an accredited investor.

The Company received net proceeds from the offering of the Note of approximately $5.965 million, after deducting estimated offering expenses.

The Note bears interest at a rate of 8.00% per annum, which accrues from September 10, 2026 until the Note is paid in full, and is payable in cash. The Note has no fixed maturity date and the Note in full or in any portion is convertible into the Company’s Class A ordinary shares, no par value per share, at the option of the holder at any time on or after September 10, 2026. The conversion price is equal to 80% of the lowest daily volume-weighted average price (VWAP) of the ordinary shares on the Nasdaq Capital Market during the three trading days ending on and including the applicable conversion date.

Conversions of the Note are subject to both (i) the Nasdaq 19.99% issuance cap under Nasdaq Listing Rule 5635 and (ii) a strict beneficial ownership limitation, meaning the holder will not have the right to convert any portion of the Note if, immediately following such conversion, the holder and its affiliates would beneficially own in excess of 9.99% of the Company’s issued and outstanding ordinary shares. Additionally, the ordinary shares issuable upon conversion of the Note are subject to a Conversion Shares Registration Cap of 12,000,000 shares.

The Notes were offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-295047), that was previously filed by the Company and became effective under the rules of the Securities and Exchange Commission (the “SEC”) on May 5, 2026. A prospectus supplement relating to the Offering was filed with the SEC and was available on the website of the SEC at www.sec.gov. Before investing in the Offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC, which provide more information about the Company and the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any unregistered conversion shares issued in excess of the registration cap will constitute “restricted securities” under the Securities Act of 1933, as amended, and may not be offered, sold, or otherwise transferred absent an effective registration statement or an available exemption from registration.

About Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Limited (“Antelope Enterprise”, “AEHL” or the “Company”) engages holds a 51% ownership position in Hainan Kylin Cloud Services Technology Co. Ltd (“Kylin Cloud”), which operates a livestreaming e-commerce business in China. For more information, please visit our website at https://aehltd.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements in this press release include, without limitation, future Bitcoin market performance and developments in the Bitcoin industry, our ability to regain customers lost resulting in a decline in our revenues, the continued stable macroeconomic environment in the PRC, the consumer and technology sectors continuing to exhibit sound long-term fundamentals, our ability to continue as a going concern, our ability to raise capital to meet our capital needs, and our ability to continue to grow our business management, information system consulting, and online social commerce and live streaming business. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 6-K for the year ended March 31, 2026 and otherwise in our SEC reports and filings. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

Contact Information:
Antelope Enterprise Holdings Limited
Xiaoying Song, Chief Financial Officer
info@aehltd.com

WFS Investor Relations Inc.
Email: services@wfsir.com
+1 628 283 9214

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment

  • James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026
  • Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical development
  • Forum convenes leading pharmaceutical scientists, device developers, and regulators focused on nasal drug delivery

SARASOTA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) — Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that James P. Kelly, MD, Chief Medical Officer, is scheduled to present at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026. The event is being held September 16–17, 2026, at Liberty House in Jersey City, New Jersey.

Dr. Kelly is scheduled to present during Session 4: Successful Case Studies, beginning at 9:40 AM ET. His presentation is expected to address the development and clinical translation of ONP-002, Oragenics’ first-in-class intranasal neurosteroid candidate for the treatment of concussion — a condition with no currently approved pharmacological treatments.

The presentation is expected to highlight the scientific rationale underlying ONP-002’s proposed mechanism of action, including its potential ability to reduce neuroinflammation, oxidative stress, and cerebral edema through the proposed simultaneous activation of multiple neuroprotective pathways. Dr. Kelly is expected to discuss the design of the Company’s proprietary breath-powered intranasal delivery device, the ongoing Phase IIa feasibility trial in Australia, and the clinical design framework for anticipated U.S. development.

ONP-002 is manufactured as a powder and delivered via a lightweight intranasal device engineered to direct the drug to the superior nasal roof for direct olfactory nerve, brain delivery, minimizing systemic exposure. A Phase IIa feasibility trial is currently enrolling at three sites in Australia, and the Company is advancing its Investigational New Drug (IND) application, with submission anticipated in Q4 2026.

Dr. Kelly stated, “The IPAC-RS Nasal Innovation Forum is an ideal venue to share the science underpinning our intranasal platform with the formulation, device, and regulatory community. Concussion represents a significant unmet need, and we are excited to present our progress toward potentially bringing the first pharmacological treatment for this condition to patients.”

The IPAC-RS Nasal Innovation Forum is an annual pharmaceutical industry forum dedicated to nasal drug delivery, convening scientists, device innovators, and regulatory experts to discuss formulation science, device technology, manufacturing best practices, and regulatory strategy.

About ONP-002

ONP-002 is a first-in-class intranasal neurosteroid being investigated for the treatment of mTBI (concussion). There are currently no FDA-approved pharmacological treatments for mTBI. ONP-002 is designed to reduce neuroinflammation, oxidative stress, and cerebral edema through gene amplification of multiple neuroprotective pathways simultaneously. The compound is spray-dry manufactured into a nanoparticle powder and delivered via a proprietary breath-powered intranasal device designed to maximize olfactory deposition and direct brain delivery while minimizing systemic exposure. Phase I single and multiple ascending dose safety trials have been completed with a favorable safety and tolerability profile. A Phase IIa feasibility trial is currently enrolling in Australia.

About Oragenics

Oragenics is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology. The Company’s lead candidate, ONP-002, is being developed as a potential first-in-class treatment for mTBI (concussion). Oragenics is advancing ONP-002 through Phase IIa clinical trials in Australia, with U.S. Phase IIb trials planned to follow pending IND submission. The Company’s intranasal delivery platform has potential applications across a range of acute and chronic neurological conditions. For more information, visit www.oragenics.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements concerning the Company’s expectations, plans, business outlook, or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance, or other matters are forward-looking statements. These statements include, but are not limited to, statements regarding the expected timing and outcomes of the Company’s Phase IIa and planned Phase IIb clinical trials, the Company’s regulatory strategy and engagement with the FDA, the anticipated timing of the Company’s IND submission, the potential applications of Oragenics’ intranasal delivery platform, and the Company’s ability to advance its clinical programs with available capital. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to the clinical development process, patient enrollment and trial execution, regulatory approval processes, the Company’s ability to secure adequate funding for operations, and those risks set forth in Oragenics’ most recent Forms 10-K, 10-Q, and other SEC filings available through EDGAR at www.sec.gov. Oragenics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release, except as may be required by law.

CONTACTS
Investor Relations
irth Communications
1-866-976-4784
IR@oragenics.com

Media Relations
irth Communications
1-866-976-4784
media@irthcommunications.com

Source: Oragenics

Autonomix Medical, Inc.

Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors

Appointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies

THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member for Autonomix.

Ms. Kalter brings more than four decades of experience across the medical device and healthcare industries, including extensive senior-level experience at Medtronic, one of the world’s largest and most diversified medical technology companies. During her tenure at Medtronic, she played a key role in regulatory, clinical and strategic initiatives spanning multiple business units and oversaw due diligence and integration activities associated with more than 27 acquisitions.

Her Medtronic experience includes supporting some of the company’s most significant and innovative technologies, including the Symplicity Spyral™ Renal Denervation system, Evolut™ TAVR platform, Micra™ Transcatheter Pacing System, and PulseSelect™ Pulsed Field Ablation system. Her experience also includes involvement with the acquisition and integration of technologies that contributed to Medtronic’s expansion of its renal denervation platforms and electrophysiology.

“Sandy brings an extraordinary level of MedTech experience to Autonomix, particularly from her time at Medtronic, where she was at the intersection of regulatory strategy, clinical development, technology evaluation and corporate transactions,” said Walter Klemp, Chairman of the Board of Autonomix. “Her firsthand understanding of how a global medical device leader evaluates emerging technologies, navigates regulatory pathways and approaches strategic partnerships and acquisitions is exceptionally valuable to Autonomix as we advance our technology and expand our relationships across the industry.”

As a Board Member, Ms. Kalter will provide strategic guidance to Autonomix’s Board and management team as the Company advances its proprietary technologies and evaluates opportunities to expand its technology across additional therapeutic applications. Her experience is also expected to support the Company’s strategic discussions with potential industry partners and other stakeholders as Autonomix continues to develop its platform.

“I am excited to join Autonomix as a Board Member at an important stage in the Company’s development,” said Sandra Cohen Kalter. “Having spent much of my career at Medtronic helping guide innovative technologies through complex regulatory, clinical and strategic processes, I understand the importance of combining strong technology with a thoughtful development and commercialization strategy. Autonomix has developed a differentiated approach to nerve sensing and targeted therapy, leveraging advanced technology to potentially revolutionize how clinicians detect, interpret and treat nerve-related conditions. I believe Autonomix is well positioned to advance this technology toward clinical development and unlock its broader potential across the medical device landscape. I look forward to working with the Board and management team as the Company moves this important technology forward.”

Extensive Medtronic Experience

During her 20 years at Medtronic, Ms. Kalter served in senior legal regulatory leadership roles, including Vice President and Chief Regulatory Counsel, advising Medtronic business units on FDA strategy, clinical and legal regulatory matters, quality systems, product development and commercialization.

Her Medtronic experience includes:

  • More than 27 acquisitions: Oversaw due diligence and integration activities for more than 27 acquisitions, including technologies that expanded Medtronic’s capabilities in renal denervation, electrophysiology and other areas of medical technology.
  • Category-defining technologies: Regulatory and strategic involvement with major Medtronic platforms including Symplicity Spyral™ Renal Denervation, Evolut™ TAVR, Micra™ Transcatheter Pacing System and PulseSelect™ PFA.
  • FDA and legal regulatory leadership: Built and managed an in-house FDA legal team supporting Medtronic’s business units and helping guide legal regulatory strategies for innovative medical technologies.
  • Strategic technology evaluation: Extensive experience evaluating emerging medical technologies and navigating the regulatory, clinical and strategic considerations involved in bringing innovative devices into major medical device portfolios.

Prior to joining Medtronic, Ms. Kalter spent 13 years as FDA/Healthcare Counsel at King & Spalding LLP, where she advised clients on complex FDA regulatory matters, including regulatory filings and FDA advisory panel proceedings.

“Sandy’s experience is particularly relevant to where Autonomix is headed,” commented Brad Hauser, Chief Executive Officer of Autonomix. “We are developing technology at the intersection of sensing, neuromodulation and minimally invasive intervention, and her experience with major platforms in renal denervation and electrophysiology gives her a unique perspective on the opportunity in front of us. We are thrilled to have her strategic insight as we work to advance Autonomix toward clinical development and ultimately position the Company for broader industry partnerships.”

Ms. Kalter received a Juris Doctor degree from The George Washington University National Law Center and a Bachelor of Science in Journalism from Northwestern University.

About Autonomix Medical, Inc. 

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements 

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the versatility and scalability of the Company’s platform technology, the potential for future clinical applications across multiple organ systems, the strength and scope of the Company’s intellectual property portfolio, and the potential for the Company’s patented technologies to support patient selection, procedural guidance and post-treatment monitoring across multiple neuromodulation applications.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact 

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

Attachment

The recognition highlights the company’s commitment to earning trust across customers, employees, and investors

KEY POINTS

  • ASUS named for the third time by Newsweek as one of the World’s Most Trustworthy Companies, reflecting strong stakeholder confidence
  • The ranking aligns with the company’s commitment to a people-first culture built on a design-thinking approach and transparent supply chain practices
  • ASUS validated for its company values, management, and long-term potential driven by its Ubiquitous AI. Incredible Possibilities. strategy

ASUS Recognized Among Newsweek’s World’s Most Trustworthy Companies for the Third Consecutive Year

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — ASUS today announced its inclusion among Newsweek’s World’s Most Trustworthy Companies in 2026, for the third consecutive year. This recognition is awarded to companies that have gained the trust of consumers, investors, and employees. It also underscores the company’s commitment to reliability and excellence in the Technology Hardware industry.

The Newsweek ranking acknowledges companies that have earned customer confidence in their products, services, advertising, communication, and complaint handling; investor confidence in company values, management, and long-term potential; and employee satisfaction with fair treatment, compensation, workplace appeal, and career development. This aligns with the ASUS commitment to a people-first culture built on a design-thinking approach and transparent supply chain practices.

“We are honored that ASUS has once again been recognized by Newsweek as one of the World’s Most Trustworthy Companies,” said S.Y. Hsu, ASUS Co-CEO. “This recognition reinforces the importance of earning confidence and creating long-term value for customers, employees, and investors through our Ubiquitous AI. Incredible Possibilities strategy as we deliver comprehensive AI solutions across Infrastructure, Physical AI, AI PCs and devices.”

“We are proud to receive this recognition from Newsweek, which underscores our commitment to responsible innovation and sustainable growth,” said Samson Hu, ASUS Co-CEO. “The company’s approach combines user-focused innovation with responsible business practices, including efforts to support a more sustainable future by designing products that balance high performance with environmental responsibility, using governance and initiatives such as our AI x ESG Platform.”

Building trust through Ubiquitous AI. Incredible Possibilities

ASUS is committed to fostering trust through its Ubiquitous AI. Incredible Possibilities. strategy, aiming to make AI accessible to everyone, everywhere. This involves delivering comprehensive AI solutions that span public and private clouds, general and personal intelligence, and seamless cloud-edge collaboration.

ASUS achieves this by designing high-performance products with environmental responsibility in mind. The company builds lasting stakeholder trust by combining innovation, AI leadership, and strong employee engagement. Bolstered by robust R&D and strategic global partnerships, ASUS maintains its leadership in AI PCs, gaming, and servers, while also providing transformative solutions across smart healthcare, cities, retail, and manufacturing, highlighting its broad global impact and earned confidence.

About Newsweek World’s Most Trustworthy Companies

The World’s Most Trustworthy Companies 2026, compiled by Newsweek in its third edition, recognizes 1,000 companies across 23 industries and 20 countries that have earned the confidence of customers, investors, and employees. The ranking evaluates companies from multiple perspectives — including customers, investors, and employees — taking into account factors such as product quality, corporate values, management competency, employee treatment, and career development opportunities. This recognition highlights companies that consistently demonstrate reliability, transparency, and strong governance.

NOTES TO EDITORS

ASUS Homepage: https://www.asus.com/ca-en/

ASUS AI PCs: https://www.asus.com/ca-en/content/asus-ai-pc/

ASUS Sustainability: https://esg.asus.com/

ASUS Pressroom: http://press.asus.com

ASUS Canada Facebook: https://www.facebook.com/asuscanada/

ASUS Canada Instagram: https://www.instagram.com/asus_ca

ASUS Canada YouTube: https://ca.asus.click/youtube

ASUS Global X (Twitter): https://www.x.com/asus

About ASUS

ASUS (2357.TW) is an innovative technology leader delivering the world’s most comprehensive AI solutions across Infrastructure, Physical AI, AI PC/Devices, and Engineering the AI Advantage. Guided by its “Ubiquitous AI. Incredible Possibilities.” strategy, ASUS is bringing enterprise-to-edge AI to life. The ASUS portfolio also includes the ROG and ProArt sub-brands, which serve gamers and creators worldwide.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/72c1ab82-6cf6-4146-af03-3283d5061dbf

CONTACT: PRESS CONTACTS

Redoine Taoussi

Senior Public Relations Manager

Redoine_Taoussi@asus.com

Sessions will highlight Orchestra BioMed’s collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) will be featured in two sessions at HRX Live 2026 — the Heart Rhythm Society’s annual innovation-focused meeting taking place September 18-20, 2026, in Atlanta, Georgia.

A sponsored roundtable will focus on Orchestra BioMed’s strategic collaboration with Medtronic to accelerate the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a cardiac pacemaker. A second panel will explore the expanding role of permanent pacing beyond bradycardia, including AVIM Therapy as an emerging cardiac pacing-based approach to treat uncontrolled hypertension and hypertensive heart disease.

Roundtable on AVIM Therapy & Medtronic Collaboration

Accelerating AVIM Therapy for Hypertensive Heart Disease: The Medtronic / Orchestra BioMed Innovation Partnership (Saturday, September 19, 2026, 9:40-10:25 a.m. ET)

  • Moderator: Vivek Reddy, MD, Director of Cardiac Arrhythmia Services, The Mount Sinai Fuster Heart Hospital; Director of Electrophysiology, Mount Sinai Health System
  • Panelists: Robert C. Kowal, MD, PhD, Vice President and General Manager of Cardiac Pacing Therapies, Medtronic Electrophysiology Therapies; Andrea Russo, MD, Academic Chief, Division of Cardiology, and Director of Cardiac Electrophysiology and Arrhythmia Services, Cooper University Hospital; Charles Love, MD, Professor of Medicine and Director of Cardiac Rhythm Device Services, Johns Hopkins Hospital; and David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed

The panel will explore AVIM Therapy’s mechanism of action and potential as a cardiac pacing-based treatment for hypertension, the most common comorbidity among pacemaker-indicated patients. Panelists will review clinical evidence showing immediate, substantial and sustained reductions in systolic blood pressure, as well as improvements in hemodynamics and cardiac function. They will also provide an update on the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) and examine the Orchestra BioMed and Medtronic collaboration as a differentiated model for accelerating medical device innovation. Dr. Reddy serves as Executive Chairman of the BACKBEAT Trial Steering Committee, Dr. Russo serves as Co-Principal Investigator of the trial, and Dr. Love serves as a member of the Steering Committee.

Dr. Reddy commented, “AVIM Therapy exemplifies the kind of innovation HRX was created to showcase. It builds on the long-established pacemaker platform, expanding cardiac pacing into hypertension therapy, a critically important area of clinical need, the leading risk factor for death worldwide, and the most common comorbidity in pacemaker patients. The BACKBEAT Trial is nearing enrollment completion, and the collaboration between Orchestra BioMed and Medtronic offers a compelling model for accelerating the development of a potentially transformative therapy for the large population of patients living with uncontrolled hypertension.”

Panel Session Featuring AVIM Therapy

Permanent Pacing but not for Bradycardia (Friday, September 18, 2026, 4:45-5:30 p.m. ET)

  • Moderator: Robert C. Kowal, MD, PhD, Vice President and General Manager of Cardiac Pacing Therapies, Medtronic Electrophysiology Therapies
  • Panelists: Prof. Karl-Heinz Kuck, MD, University Heart Center Lübeck; Andrea Russo, MD, Cooper University Hospital; Margaret Infeld, MD, Tufts Medical Center; Daniel Friedman, MD, Duke University School of Medicine; and Daniel Lustgarten, MD, PhD, University of Vermont Medical Center

This panel will explore the expanding role of permanent cardiac pacing beyond the treatment of bradycardia. AVIM Therapy will be among several emerging pacing-based applications featured in the discussion.

David Hochman, Chairman, Chief Executive Officer and Founder of Orchestra BioMed, added, “The inclusion of AVIM Therapy in two HRX Live 2026 sessions reflects growing recognition within the electrophysiology community that AVIM Therapy can play a significant role in expanding the therapeutic value of cardiac pacing. We look forward to engaging with the clinicians, innovators and industry leaders shaping the future of cardiovascular care. These discussions will focus on AVIM Therapy’s potential to address the significant unmet need among patients with uncontrolled hypertension and hypertensive heart disease.”

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities.

AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk.

Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease.

For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

About AVIM Therapy

AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company’s ongoing pivotal trials, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 12, 2026 as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in Part II of the Company’s subsequently filed quarterly reports on Form 10-Q.

Investor Contact:

Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:

Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

A third-party logistics and manufacturing provider will deploy two HEXWAVE systems at a U.S. facility in 2026, with additional systems projected for a second facility in 2027.

WILMINGTON, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, today announced that a provider of third-party logistics, warehousing and manufacturing services will deploy two HEXWAVE™ systems at one of its U.S. facilities in 2026, and is projecting additional systems for a second facility in 2027.

The customer is acquiring the systems under a financing option Liberty offers commercial customers, which lets a buyer bring screening online without a capital request. Financial terms were not disclosed. Similar to other HEXWAVE deployments, the systems are covered by a service and support agreement.

The company handles and manufactures product on behalf of its own customers, which puts customer intellectual property inside its buildings alongside its own inventory. A walk-through metal detector finds metal. HEXWAVE detects metallic and non-metallic items concealed on a person, including ceramics, plastics and powders, and reports the location by body region so the operator knows where to look.

Screening the same workforce every shift is a different problem from screening a crowd once. The HEXWAVE operator sees a generic body outline rather than a picture of the person being screened, and HEXWAVE does not store images or capture personal information about the people it screens. In the S-Configuration people follow the floor arrows through the lane at a walking pace without stopping.

“Loss prevention buys differently than other critical infrastructure applications do,” said Bill Frain, CEO of Liberty Defense. “A distribution and manufacturing operation is protecting against something that shows up on the books every quarter, and the customer almost always runs more than one building. We are not only protecting the employees, but we are safeguarding the assets. This customer is a strong fit for HEXWAVE and represents the kind of commercial market the technology was built to serve.”

HEXWAVE detects metallic and non-metallic threats using millimeter wave technology and 3D video-rate imaging, with automatic threat detection powered by AI and deep learning algorithms. It also detects contraband and other prohibited items, including liquids, powders, plastics, vapes and phones. HEXWAVE has been selected for use in aviation, government buildings, laboratories, courthouses, correctional facilities, and a range of public and commercial venues.

About Liberty Defense

Liberty Defense (NASDAQ: DETX; TSXV: SCAN) provides multi-technology security solutions for concealed weapons detection in high volume foot traffic areas and locations requiring enhanced security such as airports, stadiums, schools, and more. Liberty’s HEXWAVE product, for which the Company has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement for patents related to active 3D radar imaging technology, provides discrete, modular, and scalable protection to provide layered, stand-off detection capability of metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions.

For updates and news, please visit the Company website to subscribe to email alerts or follow Liberty Defense on social channels.

For further information about Liberty Defense, please contact:
Jay Adelaar
Senior Vice President of Capital Markets, Liberty Defense
604-809-2500
jay@libertydefense.com

For sales information, please contact:
Ian McNaughton
Senior Director Business Development, Liberty Defense
613-292-3669
imcnaughton@libertydefense.com

FORWARD-LOOKING STATEMENTS

When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because Liberty can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of Liberty.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information, including those appearing in Liberty’s public filings. Such factors include, among others: currency fluctuations; limited business history of Liberty; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; general development, market and industry conditions; and other factors described in Liberty’s public filings. Liberty undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of its securities or its financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

ATLANTA, Sept. 16, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today announced that it has been awarded a task order to continue providing high-quality information technology services for the National Heart, Lung, and Blood Institute (“NHLBI”).

DLH has performed on this mission since 2018. The task order, valued at up to $43.7 million, includes a base period and multiple options aggregating to a two-and-a-half-year period of performance. The Company will provide services in support of approximately 2,000 NHLBI scientific and administrative employees and contractors.

Under this task order, DLH will build on its existing implementation of artificial intelligence for IT operations (“AIOps”) and automation to improve service efficiency, system reliability, data integrity, cybersecurity, and compliance. Services include:

  • Scientific technology support
  • Application support services
  • Tiered service desk
  • Configuration management
  • Infrastructure operations across on-premises and cloud environments
  • Cybersecurity operations

“By combining scientific expertise with cloud, cybersecurity, application support, and AIOps capabilities, DLH remains a trusted partner for customers seeking mission-critical federal health technology services,” said DLH President & CEO Kathryn JohnBull. “We are pleased that this award extends our longstanding relationship with NHLBI. We expect to continue driving technology modernization, improved operating efficiency through automation, and reduced risk in support of the organization’s critical biomedical research mission.”

About DLH

DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.

Contact Information:

Investor Relations

investorrelations@dlhcorp.com

Media

communications@dlhcorp.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding expected contract performance, future task order value, and anticipated operational benefits. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.

SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares (“the Offering”), all of which are being offered by CUPR at a public offering price of $1.15 per share (“the Offering Price”), for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses.

The Company has granted the underwriter a 45-day option to purchase up to an additional 648,373 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (“the Over-allotment”). Assuming that the Over-allotment is exercised, the Company is expected to receive gross proceeds amounting to approximately $5.72 million, before deducting underwriting discounts and commissions and estimated offering expenses.

The Offering is expected to close on or about September 17, 2026, subject to the satisfaction of customary closing conditions.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”), acted as the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, Harney Westwood & Riegels Singapore LLP are acting as U.S., Singapore and Cayman Islands legal counsels to the Company, respectively, and Ellenoff Grossman & Schole LLP is acting as U.S. legal counsel to R. F. Lafferty for the Offering.

The Offering is being conducted pursuant to the Company’s Registration Statement on Form F-1 (File No: 333-297299) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 15, 2026. The Offering is being made only by means of a prospectus. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. Copies of the final prospectus related to the Offering may be obtained, when available, from R. F. Lafferty & Co., Inc., 40 Wall Street, Suite 3602, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected completion, timing and gross proceeds of the offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact

Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.